Comparison of Blood Loss Following Total Hip Arthroplasty With the Use of Three Thromboprophylactic Regimes: Dabigatran, Enoxaparin and Rivaroxaban.

• Status: Unknown status
• Trial end date: 2014-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine which of the following drugs: enoxaparin, dabigatran and rivaroxaban causes least blood loss after total hip replacement (THR).

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre of Postgraduate Medical Education
• Treatments: Dabigatran; Enoxaparin; Rivaroxaban

Criteria

Inclusion Criteria:

• primary, end-stage hip osteoarthritis requiring total hip arthroplasty

Exclusion Criteria:

• inflammatory arthropathies

• liver disorders

• neoplastic conditions

• clotting disorders